Hypofractionated stereotactic radiotherapy versus whole-brain radiotherapy following brain metastasis resection: Results of the ESTRON randomized phase 2 trial
Open Access
- 30 July 2025
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (12) , 3224-3236
Abstract
Background: Postoperative radiotherapy improves local control after brain metastasis (BM) resection. Whole-brain radiotherapy (WBRT) reduces recurrence risk but impairs neurocognition. Hypofractionated stereotactic radiotherapy of the cavity (HFSRT) may offer equivalent tumor control with reduced toxicity. ESTRON is the first randomized trial comparing post-operative HFSRT and WBRT. Methods: This single-center phase 2 trial randomized 56 patients with resected BM to receive HFSRT (35 Gy in 7 fractions) or WBRT (30 Gy in 10 fractions). Patients could have ≤ 10 additional unresected BMs. The primary endpoint was intracranial progression-free survival (ic-PFS). Secondary endpoints included local control (LC), overall survival (OS), leptomeningeal disease (LMD), and toxicity. Results: Fifty-four patients were evaluable (n = 27 per arm). At 24.7 months median follow-up, 12-month ic-PFS was 44.4% (HFSRT) versus 59.3% (WBRT) (HR 1.72, P = .080). Median ic-PFS was 4.7 versus 15.0 months. LC at 24 months was 94.1% (HFSRT) versus 85.4% (WBRT) (HR 0.41, P = .433). One-year OS was 63.0% (HFSRT) versus 77.8% (WBRT), with no significant difference in median OS (17.8 vs 27.0 months; HR 1.09, P = .336). One-year risk of LMD was 27.0% (HFSRT, predominantly outside the irradiated field) versus 8.7% (WBRT) (log-rank P = .03). Treatment-related adverse events were more frequent with WBRT (115 vs 54 events), including 19% versus 11% grade 3 events, and poorer neurocognitive performance. Conclusions: Survival was similar for HFSRT and WBRT, while WBRT trended toward better ic-PFS. HFSRT showed substantially lower toxicity and better neurocognitive preservation, however, a higher risk of LMD. Risks and benefits should be weighed individually when determining post-operative treatment for BM.Keywords
Funding Information
- Accuray Inc
This publication has 49 references indexed in Scilit:
- Postoperative stereotactic radiosurgery (SRS) vs hypofractionated stereotactic radiotherapy (SRT) for resected brain metastases – a single centre analysisClinical & Experimental Metastasis, 2025
- EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumoursAnnals of Oncology, 2021
- Multi-institutional Analysis of Prognostic Factors and Outcomes After Hypofractionated Stereotactic Radiotherapy to the Resection Cavity in Patients With Brain MetastasesJAMA Oncology, 2020
- Fractionated stereotactic radiotherapy for local control of resected brain metastasesJournal of Neuro-Oncology, 2019
- Postoperative hypofractionated stereotactic brain radiation (HSRT) for resected brain metastases: improved local control with higher BED10Journal of Neuro-Oncology, 2018
- Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resectionCancer Medicine, 2018
- Multicenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastasesCancer Medicine, 2018
- HFSRT of the resection cavity in patients with brain metastasesStrahlentherapie und Onkologie, 2016
- Hopkins Verbal Learning Test2011
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996